Approximately 20% of breast cancers demonstrate amplification of the proto-oncogene HER2, a receptor tyrosine kinase (RTK) belonging to the epidermal growth factor receptor (EGFR) family, and approximately 30% of HER2-positive tumors show DM amplification [70, 73]. This evidence concerns the gene EGFR and breast carcinoma.